
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
The current MNLO market cap is 19.91M. The company's latest EPS is USD -2.7004 and P/E is -0.65.
Quarter End | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Revenue | 76k | 98k | 198k | 121k | 84k |
Operating Income | -6.83M | -7.38M | -10.4M | -13.09M | -12.77M |
Net Income | -6.19M | -6.25M | -9.41M | -12.16M | -12.02M |
Year End 31 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Revenue | 20.99M | 14.76M | 477k | 424k | 501k |
Operating Income | -198.2M | -68.03M | -34.3M | -29.26M | -43.64M |
Net Income | -255.83M | -73.33M | -23.21M | -28.45M | -39.83M |
Quarter End | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Assets | 97.69M | 91.68M | 86.65M | 76.2M | 66.91M |
Total Liabilities | 8.95M | 8.31M | 11.78M | 12.66M | 14.82M |
Total Equity | 88.74M | 83.37M | 74.87M | 63.54M | 52.09M |
Year End 31 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Assets | 93.74M | 67.05M | 40.76M | 97.69M | 66.91M |
Total Liabilities | 56.25M | 18.41M | 9.35M | 8.95M | 14.82M |
Total Equity | 37.49M | 48.64M | 31.2M | 88.74M | 52.09M |
Quarter End | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Operating | -25.34M | -7.98M | -16.46M | -24.97M | -33.97M |
Investing | -57.35M | -3.57M | 15.45M | 10.63M | 23.37M |
Financing | 82.39M | -4k | -7k | -9k | -141k |
Year End 31 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Operating | -137.08M | -56.37M | -29.2M | -25.34M | -33.97M |
Investing | 89.11M | 1.03M | 15.67M | -57.35M | 23.37M |
Financing | 61.81M | 39.78M | 1.65M | 82.39M | -141k |
Market Cap | 19.91M |
Price to Earnings Ratio | -0.65 |
Price to Sales Ratio | 51.76 |
Price to Cash Ratio | 1.3 |
Price to Book Ratio | 0.5 |
Dividend Yield | - |
Shares Outstanding | 14.75M |
Average Volume (1 week) | 0 |
Average Volume (1 Month) | 0 |
52 Week Change | - |
52 Week High | - |
52 Week Low | - |
Spread (Intraday) | 0.01 (0.73%) |
Company Name | Menlo Therapeutics Inc |
Address |
1521 concord pike suite 201 wilmington, delaware 19810 |
Website | https://vynetherapeutics.com |
Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions